Concepedia

Publication | Open Access

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*

DOIFull Paper Access

11

Citations

25

References

2014

Year

Sibylle Loibl, Dennis Rokitta, Bettina Conrad, Nadia Harbeck, Michaela Wüllner, Mathias Warm, Kathrin Schwedler, Bernd Gerber, Iris Schrader, Holger Eidtmann,
Breast Care

Abstract

Sorafenib EC-Pw is feasible if the starting dose is 200 mg, escalated every 3 weeks based on the patients' individual toxicities.

References

YearCitations

Page 1